Bergqvist A
Department of Obstetrics and Gynecology, Huddinge University Hospital, S-141 86, Huddinge, Sweden.
Gynecol Endocrinol. 2000 Dec;14(6):425-32. doi: 10.3109/09513590009167714.
The effects of goserelin and nafarelin were compared in a prospective, randomized, open, parallel study of 6 months' treatment of 252 women with symptomatic, laparoscopically proven endometriosis. Twenty-eight departments of obstetrics and gynecology in Sweden, Norway, Denmark and Finland were included. Evaluations were made every 3 months for quantification of pain, bleeding and adverse events and convenience of treatment, and at 3 months after the end of treatment, when a control laparoscopy was performed for evaluation of changes in endometriotic lesion size, color and location. Thirty-nine patients withdrew and 113 women given goserelin and 100 women given nafarelin completed the study. There were no statistically significant differences between the groups, either in adverse events or in bleeding. There were no correlations between location, lesion size or type of lesion, and symptom score in either group, or between treatments with regard to change in endometriosis score. In both groups, the percentage of red and black lesions was reduced while the proportion of white lesions increased. The pain score was significantly reduced in both groups. Local irritation in the nasal mucosa was reported in both groups, mostly in the nafarelin-treated group. The goserelin-treated group also reported local symptoms at the injection site. We conclude that there is no statistically significant difference in treatment results or side-effects between goserelin and nafarelin when used for the treatment of endometriosis.
在一项前瞻性、随机、开放、平行研究中，比较了戈舍瑞林和那法瑞林对252例有症状且经腹腔镜证实患有子宫内膜异位症的女性进行6个月治疗的效果。该研究纳入了瑞典、挪威、丹麦和芬兰的28个妇产科科室。每3个月进行一次评估，以量化疼痛、出血和不良事件以及治疗的便利性，并在治疗结束后3个月进行对照腹腔镜检查，以评估子宫内膜异位症病变大小、颜色和位置的变化。39例患者退出研究，113例接受戈舍瑞林治疗的女性和100例接受那法瑞林治疗的女性完成了研究。两组在不良事件或出血方面均无统计学显著差异。两组中病变的位置、大小或类型与症状评分之间均无相关性，治疗之间在子宫内膜异位症评分变化方面也无相关性。两组中红色和黑色病变的百分比均降低，而白色病变的比例增加。两组的疼痛评分均显著降低。两组均报告有鼻黏膜局部刺激，大多发生在接受那法瑞林治疗的组中。接受戈舍瑞林治疗的组也报告了注射部位的局部症状。我们得出结论，戈舍瑞林和那法瑞林用于治疗子宫内膜异位症时，在治疗结果或副作用方面无统计学显著差异。
